These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35489798)

  • 1. If aspirin-exacerbated respiratory disease treatment is a jigsaw puzzle, where do the aspirin and biologic pieces go?
    White AA
    Ann Allergy Asthma Immunol; 2022 May; 128(5):484-485. PubMed ID: 35489798
    [No Abstract]   [Full Text] [Related]  

  • 2. Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease.
    Ghiasi Y; Wangberg H; Bagsic SRS; White A
    Ann Allergy Asthma Immunol; 2022 Nov; 129(5):642-643. PubMed ID: 35908738
    [No Abstract]   [Full Text] [Related]  

  • 3. Leukotriene-Associated Rash in Aspirin-Exacerbated Respiratory Disease.
    Laidlaw TM; Gakpo DH; Bensko JC; Buchheit K
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3170-3171. PubMed ID: 32739465
    [No Abstract]   [Full Text] [Related]  

  • 4. A retrospective analysis of bronchiectasis in patients with aspirin-exacerbated respiratory disease.
    Chen YS; Bensko JC; Laidlaw TM; Buchheit KM
    J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2799-2801. PubMed ID: 32330669
    [No Abstract]   [Full Text] [Related]  

  • 5. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.
    Patel P; Bensko JC; Bhattacharyya N; Laidlaw TM; Buchheit KM
    Ann Allergy Asthma Immunol; 2022 Mar; 128(3):326-328. PubMed ID: 34863953
    [No Abstract]   [Full Text] [Related]  

  • 6. Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease.
    Mustafa SS; Vadamalai K
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):738-739. PubMed ID: 33746062
    [No Abstract]   [Full Text] [Related]  

  • 7. Age as a factor in treatment of aspirin-exacerbated respiratory disease: relationship to required aspirin maintenance dose after desensitization.
    Locke TB; Sweis AM; Gleeson PK; Lin TC; Civantos AM; Parhar HS; Corr AM; Kumar A; Salmon MK; Kohanski MA; Palmer JN; Bosso JV; Adappa ND
    Int Forum Allergy Rhinol; 2020 Oct; 10(10):1180-1181. PubMed ID: 32761891
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 in a series of patients with aspirin-exacerbated respiratory disease.
    White AA; Cahill KN; Jerschow E; Kuruvilla M; Sehanobish E; Bensko J; Laidlaw TM; Levy JM
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2900-2903. PubMed ID: 33965591
    [No Abstract]   [Full Text] [Related]  

  • 9. Multidisciplinary single-center outcomes compared to two-center outcomes for the treatment of aspirin exacerbated respiratory disease.
    Bosso JV; Tripathi SH; Kennedy DW; Kohanski MA; Cohen NA; Palmer JN; Adappa ND
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2498-2500. PubMed ID: 33548515
    [No Abstract]   [Full Text] [Related]  

  • 10. Aspirin-Exacerbated Respiratory Disease: The Hunt for the "Rosetta Stone" of Respiratory Inflammation.
    White AA
    Immunol Allergy Clin North Am; 2016 Nov; 36(4):xv-xvi. PubMed ID: 27712771
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypereosinophilia following aspirin desensitization for aspirin-exacerbated respiratory disease.
    Pitlick MM; Pongdee T
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2187-2190.e1. PubMed ID: 35598867
    [No Abstract]   [Full Text] [Related]  

  • 12. Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumab.
    Bensko JC; McGill A; Palumbo M; Cahill KN; Laidlaw TM
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2466-2468. PubMed ID: 35643277
    [No Abstract]   [Full Text] [Related]  

  • 13. Poor control of asthma symptoms with interleukin-5 inhibitors in four patients with aspirin-exacerbated respiratory disease.
    Eid RC; Wudneh E; Zahid S; Cahill K; Jerschow E
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):102-104. PubMed ID: 31605753
    [No Abstract]   [Full Text] [Related]  

  • 14. Aspirin-Exacerbated Respiratory Disease.
    White AA; Stevenson DD
    N Engl J Med; 2018 Sep; 379(11):1060-1070. PubMed ID: 30207919
    [No Abstract]   [Full Text] [Related]  

  • 15. Aspirin-exacerbated respiratory disease: not always "adult-onset".
    Tuttle KL; Schneider TR; Henrickson SE; Morris D; Abonia JP; Spergel JM; Laidlaw TM
    J Allergy Clin Immunol Pract; 2016; 4(4):756-8. PubMed ID: 27393784
    [No Abstract]   [Full Text] [Related]  

  • 16. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease.
    Guillén D; Bobolea I; Calderon O; Fiandor A; Cabañas R ; Heredia R; Quirce S
    J Investig Allergol Clin Immunol; 2015; 25(2):133-5. PubMed ID: 25997307
    [No Abstract]   [Full Text] [Related]  

  • 17. Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease.
    Corey KB; Turner JH; Chowdhury NI; Chandra RK; Li P; Wu P; Cahill KN
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1644-1645.e1. PubMed ID: 35398556
    [No Abstract]   [Full Text] [Related]  

  • 18. Aspirin desensitization for aspirin-exacerbated respiratory disease in the era of biologics: Clinical perspective.
    Bosso JV
    Int Forum Allergy Rhinol; 2021 Apr; 11(4):822-823. PubMed ID: 33070455
    [No Abstract]   [Full Text] [Related]  

  • 19. Current complications and treatment of aspirin-exacerbated respiratory disease.
    Cook KA; Stevenson DD
    Expert Rev Respir Med; 2016 Dec; 10(12):1305-1316. PubMed ID: 27817219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin-exacerbated respiratory disease: personalized medical and surgical approaches.
    Schlosser RJ
    Int Forum Allergy Rhinol; 2020 Sep; 10(9):1035-1036. PubMed ID: 32634286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.